Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Small Cell Lung Carcinoma

Melanoma

Sarcoma

Carcinoma, Small Cell

Lung Neoplasms

Carcinoid Tumor

Parathyroid Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neoplasms, Connective and Soft Tissue

Adenocarcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Endocrine System Diseases

Parathyroid Diseases

Small Cell Lung Cancer

Soft Tissue Sarcoma

Parathyroid Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Bortezomib

Dacarbazine

Antineoplastic Agents, Alkylating

Alkylating Agents

Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2

Dacarbazine and bortezomib

Andrew Poklepovic, MD

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.

The primary objective is to determine recommended phase II doses for the combination dacarbazine and bortezomib administered weekly.

Secondary objectives are to determine the maximum tolerated dose combination and to observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	NCT00580320	Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor...	Dacarbazine and...	18 Years -	Virginia Commonwealth University
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	NCT00580320	Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor...	Dacarbazine and...	18 Years -	Virginia Commonwealth University

Spots Global Cancer Trial Database for dacarbazine and bortezomib